NasdaqGS:VTRSPharmaceuticals
How Effexor’s New GAD Approval And MR-139 Setback At Viatris (VTRS) Has Changed Its Investment Story
In March 2026, Viatris announced that Japan's Ministry of Health, Labour and Welfare approved Effexor SR capsules for treating adults with generalized anxiety disorder, making it the first and only approved GAD therapy in Japan based on positive Phase 3 data in Japanese patients.
This approval highlights Viatris's ability to expand indications for existing medicines into areas of unmet need, while its pipeline progress in Japan contrasts with setbacks such as the recent Phase 3 failure of...